Previously submitted to: JMIR Public Health and Surveillance (no longer under consideration since Apr 06, 2023)
Date Submitted: Nov 26, 2022
Open Peer Review Period: Nov 19, 2022 - Dec 3, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
It is Time to Attach Importance to Effects of Cardiovascular Diseases Among People living with HIV Infection: A Systematic Review and Meta-analysis
ABSTRACT
Background:
Various non-acquired immunodeficiency syndrome-related diseases, such as cardiovascular disease (CVD), affect the quality of life in people living with HIV (PLWH) and prognosis of acquired immunodeficiency syndrome (AIDS) in the post-active antiretroviral therapy (ART) era. However, little is known about the specific risk ratio between PLWH and HIV-negative individuals. We aimed to incorporate the evidence of HIV-related CVD and explore the risk factors.
Objective:
We systematically reviewed the evidence supporting the specific risk of CVD in PLWH.
Methods:
The PubMed, Embase, Web of Science, and Cochrane Library databases were searched to find cohort and cross-sectional studies that evaluated the risk of hypertension, dyslipidemia, coronary atherosclerosis diseases (CAD), and myocardial infarction (MI) in PLWH. The relative risk (RR), hazard rate (HR), odds ratio (OR), and 95% confidence interval (CI) were calculated for each study, and all were pooled using the random-effects model due to the expected variability among eligible studies. Subgroup and meta-regression analyses were performed to assess for heterogeneity.
Results:
A total of 29 studies that met the inclusion criteria were analyzed, which included 300,274 HIV-positive and 39,256,498 HIV-negative individuals. Compared with people without HIV, PLWH were associated with a higher risk of hypertension (HR = 1.28, 95% CI: 1.03–1.58), dyslipidemia (HR = 1.64, 95% CI: 1.38–1.94), CAD (HR = 1.37, 95% CI: 1.24–1.51), and MI (HR = 1.48, 95% CI: 1.28–1.72). Age, gender, body mass index (BMI) , region, smoking and time to initiate therapy had an impact on the risk of CVDs in PLWH. With aging, the pooled risk of hypertension and dyslipidemia slightly increased, while CAD decreased. Men with AIDS generally have a higher risk of hypertention(HR = 1.27, 95% CI: 1.01–1.61) and dyslipidemia(HR = 1.86, 95% CI: 1.56–2.22). A high BMI (obese/overweight) evidently increased the risk of dyslipidemia in PLWH (HR = 2.53, 95% CI: 1.43–4.47). The risks significantly varied in different regions, but PLWH generally had a higher risk of developing CVDs, especially hypertension and hyperlipidemia. And smoking explicitly related to the increased risk of most CVDs, except for hypertension. The earlier initiation of ART helps to decrease the risk of CVDs in PLWH. Significant heterogeneity was observed across studies for all outcomes analyzed (I2> 70%, P < 0.001), which was only partly explained by the available study-level characteristics.
Conclusions:
The risk of CVD in PLWH is higher than that in the general population. Different targeted prevention strategies for CVD should be adopted according to the risk characteristics of PLWH of different ages in different regions. The HR of CVD in the post-ART era is relatively reduced, while the risk of dyslipidemia, CAD, and MI increases slightly with smoking. For dyslipidemia in PLWH, the risk increased in men and in people with a high BMI.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.